TABLE 3.
Baseline mRNA levels in the three treatment groups.
| mRNA | Placebo |
5.9% THC |
13.4% THC |
Analysis |
| (N = 11) | (N = 4) | (N = 8) | ||
| CB1 | 8.93 ± 15.54 | 6.47 ± 5.59 | 2.45 ± 1.69 | F = 0.771, df = 2.20, P = 0.476 |
| CB2 | 248.77 ± 179.16 | 419.42 ± 262.17†b | 148.10 ± 73.42b | F = 3.486, df = 2.20, P = 0.050 |
| DNMT1 | 129.45 ± 109.35 | 69.29 ± 38.08 | 114.09 ± 92.16 | F = 0.579, df = 2.20, P = 0.569 |
| DNMT3A | 391.44 ± 408.32 | 238.62 ± 160.55 | 293.29 ± 233.74 | F = 0.403, df = 2.20, P = 0.674 |
| IL1B | 179.83 ± 186.75 | 228.49 ± 246.05 | 130.56 ± 103.51 | F = 0.449, df = 2.20, P = 0.645 |
| NR3C | 406.01 ± 320.47 | 201.60 ± 137.64 | 214.37 ± 123.88 | F = 1.852, df = 2.20, P = 0.183 |
| TET1 | 33.09 ± 22.95 | 15.98 ± 10.92 | 18.12 ± 13.10† | F = 2.085, df = 2.20, P = 0.150 |
| TET3 | 165.58 ± 125.90 | 89.15 ± 47.10 | 75.88 ± 57.29† | F = 2.243, df = 2.20, P = 0.132 |
| TNFα | 532.38 ± 480.38 | 366.40 ± 242.32 | 445.56 ± 257.26 | F = 0.306, df = 2.20, P = 0.740 |
Each value is mean±SD (ddCt = 2^(−dt) × 104). F is overall analysis for treatment effect. Difference between 5.9 and 13.4 THC vs. placebo: *P < 0.05, †P < 0.10.
Difference between 5.9 and 13.4 THC groups: bP < 0.05.
For CB1 Placebo was non-normally distributed and non-parametric Kruskal–Wallis tests also showed no significant difference: H = 4.536, df = 2, P = 0.104.